Safety , tolerability , and immunogenicity after 1 and 2 doses of zoster vaccine in <font color="red">healthy_5</font> <font color="red">adults_5</font> <font color="red">≥60_5</font> <font color="red">years_5</font> <font color="red">of_5</font> <font color="red">age_5</font> <font color="red">._5</font> 
<br>
<br> BACKGROUND Incidence and severity of herpes zoster ( HZ ) and postherpetic neuralgia increase with age , associated with <font color="red">age_1</font> <font color="red">-_1</font> <font color="red">related_1</font> <font color="red">decrease_1</font> <font color="red">in_1</font> <font color="red">immunity_1</font> <font color="red">to_1</font> <font color="red">varicella_1</font> <font color="red">-_1</font> <font color="red">zoster_1</font> <font color="red">virus_1</font> <font color="red">(_1</font> <font color="red">VZV_1</font> <font color="red">)_1</font> <font color="red">._1</font> One dose of zoster vaccine ( ZV ) has demonstrated substantial protection against HZ ; this study examined impact of a second dose of ZV . 
<br> METHODS <font color="red">Randomized_1</font> <font color="red">,_1</font> <font color="red">double_1</font> <font color="red">-_1</font> <font color="red">blind_1</font> <font color="red">,_1</font> <font color="red">multicenter_3</font> <font color="red">study_3</font> <font color="red">with_3</font> <font color="red">210_6</font> <font color="red">subjects_6</font> <font color="red">≥60_6</font> <font color="red">years_6</font> <font color="red">old_6</font> <font color="red">compared_1</font> <font color="red">immunity_1</font> <font color="red">and_1</font> <font color="red">safety_1</font> <font color="red">profiles_1</font> <font color="red">after_1</font> <font color="red">one_1</font> <font color="red">and_1</font> <font color="red">two_1</font> <font color="red">doses_1</font> <font color="red">of_1</font> <font color="red">ZV_1</font> <font color="red">,_1</font> <font color="red">separated_1</font> <font color="red">by_1</font> <font color="red">6_1</font> <font color="red">weeks_1</font> <font color="red">,_1</font> <font color="red">vs._1</font> <font color="red">placebo_1</font> <font color="red">._1</font> Immunogenicity was evaluated using VZV interferon - gamma ( IFN-γ ) enzyme - linked immunospot ( ELISPOT ) assay and VZV glycoprotein enzyme - linked immunosorbent antibody ( gpELISA ) assay . Adverse experiences ( AEs ) were recorded on a standardized Vaccination Report Card . 
<br> RESULTS No serious vaccine - related AEs occurred . VZV IFN-γ ELISPOT geometric mean count ( GMC ) of spot - forming cells per 10(6 ) peripheral blood mononuclear cells increased in the ZV group from 16.9 prevaccination to 49.5 and 32.8 at 2 and 6 weeks postdose 1 , respectively . Two weeks , 6 weeks and 6 months postdose 2 , GMC was 44.3 , 42.9 , and 36.5 , respectively . GMC in the placebo group did not change during the study . The peak ELISPOT response occurred ∼2 weeks after each ZV dose . The gpELISA geometric mean titers ( GMTs ) in the ZV group were higher than in the placebo group at 6 weeks after each dose . Correlation between the IFN-γ ELISPOT and gpELISA assays was poor . 
<br> CONCLUSIONS ZV was generally well - tolerated and immunogenic in <font color="red">adults_1</font> <font color="red">≥60_1</font> <font color="red">years_1</font> <font color="red">old_1</font> <font color="red">._1</font> A second dose of ZV was generally safe , but did not boost VZV - specific immunity beyond levels achieved postdose 1 .